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Background and Purpose: Endovascular treatment of tandem occlusions is
an emerging option. We describe our multicenter experience with endovascular
management of atherosclerotic tandem occlusions in the anterior circulation, particularly
the technical aspects and complications in comparison to isolated intracranial
occlusions.
Materials and Methods: Consecutive patients with tandem occlusions due to
atherosclerotic causes who underwent mechanical thrombectomy at two major stroke
centers between January 2010 and September 2015 were reviewed. Clinical data,
procedural aspects, recanalization rates, complication rates, and clinical outcome were
analyzed and compared to findings in patients with isolated intracranial occlusions.
Results: One hundred and twenty-one patients with tandem occlusions and 456
patients with isolated intracranial occlusions (carotid-T/M1) were included. Mean
intervention time was faster (33min vs. 57min, p < 0.001) and recanalization success
was higher (TICI 2b/3 83.6 vs. 70.2%, p = 0.002) in patients with isolated occlusions.
No difference was seen in clinical outcome and complications, except for a higher rate of
asymptomatic hemorrhage in the tandem group (29.8 vs. 17.1%, p = 0.003). Choice
of recanalization approach (antegrade vs. retrograde) in the tandem group made no
difference, except for a trend toward less distal emboli using the retrograde approach
(4.0 vs. 13.0%, p = 0.082). Stenting of the extracranial internal carotid artery (ICA) was
performed in 81%, PTA alone in 7.4%, and deferred stenting in 11.6%. Rate of stent/ICA
occlusion within 7 days was 10.3% after stenting and 33.3% after PTA (p= 0.127). In the
tandem group, age (p = 0.034), National Institutes of Health Stroke Scale score (NIHSS)
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at admission (p = 0.002), recanalization rate (p < 0.001), complications (p = 0.016),
and symptomatic intracranial hemorrhage (sICH) (p = 0.001) were associated with poor
outcome, whereas extracranial treatment modality and stent/ICA occlusion within 7 days
did not affect outcome.
Conclusion: Endovascular treatment of tandem occlusions is technically feasible,
achieves recanalization rates and rates of good clinical outcome comparable to those
in patients with isolated intracranial occlusions. Following acute ICA stenting, the risk of
stent occlusion and sICH appeared to be low, but was associated with an increased rate
of asymptomatic ICH.
Keywords: stroke, endovascular treatment, tandem occlusion, thrombectomy, stenting
INTRODUCTION
Acute tandem occlusions of the extracranial internal carotid
artery (ICA) due to an atherosclerotic lesion combined with
an intracranial ICA/middle cerebral artery (MCA) occlusion
cause a severe form of ischemic stroke associated with high
rates of disability and death. Endovascular treatment with stent
retrievers, with or without concomitant extracranial stenting of
the underlying arteriosclerotic lesion, is an emerging treatment
option for this complex form of ischemic stroke (1–8). However,
endovascular treatment is challenging and optimal treatment
strategies to enhance recanalization rates and to avoid peri-
procedural complications, thus improving clinical outcome, are
still uncertain.
Several recent randomized-controlled trials have shown the
superiority of endovascular treatment of large vessel occlusions
in acute ischemic stroke of the anterior circulation using
stent-retriever thrombectomy over intravenous thrombolysis
(9–13). Due to the greater severity of this form of stroke
and the technical complexity of endovascular treatment of
tandem occlusions, this subgroup of stroke patients has
been systematically excluded from most of the randomized-
controlled trials. Endovascular recanalization in these patients
is technically feasible, but is more complex than in those
with isolated intracranial large vessel occlusion (1, 8, 14–
16).
Therefore, consensus has yet to be reached on optimal
treatment strategies to maximize recanalization success
while minimizing treatment-related complications, such as
distal cerebral thromboembolic events, stent occlusion, and
symptomatic intracranial hemorrhage (sICH).
The purpose of the present multicenter study was to
compare stroke patients with acute tandem occlusions
due to an atherosclerotic cervical lesion and patients with
isolated carotid-T/M1 occlusions undergoing endovascular
recanalization. Comparisons were made of clinical and
imaging data, procedural aspects, recanalization rates,
complication rates, and clinical outcome. In addition, we
reviewed our experience of the endovascular management of
atherosclerotic tandem occlusions of the anterior circulation
paying special regard to technical and peri-procedural
aspects.
MATERIALS AND METHODS
Patient Selection
Records of all patients presenting with anterior circulation
ischemic stroke who were treated with an endovascular approach
at two separate institutions between January 2010 and September
2015 were retrospectively retrieved from prospectively
maintained stroke databases. The registry was approved by
the local ethics committee (Kantonale Ethikkommission für die
Forschung Bern, Bern, Switzerland, amendment access number:
231/2014) and included baseline patients characteristics, risk
factors, time metrics, and recorded clinical data). Consecutive
patients with extra-intracranial tandem occlusions due to an
atherosclerotic cervical lesion who underwent mechanical
stent-retriever thrombectomy with or without extracranial stent
implantation and patients with isolated occlusions of the anterior
circulation (i.e., carotid-T and M1 segments of the MCA) were
reviewed and included in this study.
Endovascular therapy was performed immediately after
computed tomography (CT) or magnetic resonance imaging
(MRI) if: (1) diagnosis of ischemic stroke was established
by CT/CT angiography (CTA)/CT perfusion or MRI/MR
angiography (MRA)/MR perfusion imaging; (2) baseline
National Institutes of Health Stroke Scale (NIHSS) score was ≥4
or isolated aphasia or hemianopia was present; (3) hemorrhage
had been excluded by cranial CT or MRI; (4) symptom duration
was not longer than 24 h; (5) no clinical or premorbid conditions
or laboratory findings contraindicated treatment; (6) isolated
intracranial large vessel occlusion or tandem occlusion of
the carotid-T or M1 segment associated with cervical ICA
obstruction or occlusion related to ICA atheromatosis was
demonstrated by initial imaging and/or peri-interventional
angiograms.
Decision-Making and Imaging
Initial NIHSS was assessed by a dedicated stroke neurologist.
CT and MRI were used according to the center’s protocol.
The routine CT imaging protocol consisted of unenhanced
CT scan and CTA as well as CT perfusion. The routine
MRI protocol consisted of diffusion weighted imaging (DWI),
fluid-attenuated inversion recovery (FLAIR), T2∗/susceptibility-
weighted imaging (SWI), contrast-enhanced MR angiography
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including the supra-aortic trunks, and MR perfusion imaging.
If tandem occlusion was suspected from initial imaging, it was
confirmed with digital subtraction angiography (DSA) based on
the morphological aspect of the cervical segment of the internal
carotid artery (ICA) associated with a proximal intracranial
vessel occlusion (carotid termination, M1 segment). Diagnosis
of atherosclerotic lesions was based on clinical, imaging, and
angiographic data. In particular, we aimed to distinguish
dissection from atheromatous cervical carotid artery lesions.
Intravenous Thrombolysis (IVT)
IVT (0.9 mg/kg; 10% of the dose as a bolus and the remainder
over 60min) was administered to patients within a maximum
of 4.5 h after stroke onset. Conventional clinical and laboratory
inclusion and exclusion criteria for IVT were applied.
Endovascular Procedure
Our general technical approach to address tandem lesions
in acute ischemic stroke is described elsewere (17). In
brief, endovascular treatment was performed under general
anesthesia or conscious sedation. The decision on type of
sedation was made on an individual basis by the neurologist,
-neuroradiologist, and anesthesiologist on call. DSA was
performed via a transfemoral approach using a biplane,
high-resolution angiography system. An 8 French guiding
catheter or an 8 or 9 French balloon-guiding catheter
(Guider Softip XF, Boston Scientific, Marlborough, USA; Merci,
Concentric Medical, Mountain View, USA) was introduced
into the common carotid artery and an angiographic run
was performed to evaluate the occlusion. During this step,
cervical ICA occlusion/stenosis was demonstrated and eventually
differentiated from carotid contrast agent stagnation related
to isolated carotid termination thrombus. Taking into account
both clinical data and angiographic morphology, atheromatous
occlusion was distinguished from ICA dissection.
In general, a retrograde revascularization approach (distal-to-
proximal approach), i.e., first, recanalization of the intracranial
occlusion by mechanical thrombectomy after passing through
the stenosis and secondly, addressing the cervical ICA lesion,
was used whenever primary passing of the atheromatous lesion
was technically feasible. A 0.021 “microcatheter (Headway,
MicroVention Terumo, Aliso Viejo, USA; Prowler Select Plus,
Codman & Shurtleff, Raynham, USA) was navigated through
the stenosis over a 0.014” microwire (Transend 014, Boston
Scientific, Marlborough, USA; Traxcess, MicroVention, Aliso
Viejo, USA; Silverspeed-14, ev3, Irvine, USA). This maneuver
was performed under flow arrest either through wedging
of the guide catheter in the stenosis, or inflation of the
balloon-guide catheter to avoid thromboembolic events during
crossing of the stenosis. Once the microcatheter position
distally had been confirmed by a careful contrast injection,
an intermediate 5 or 6 French guiding catheter (5max and
5max ACE, Penumbra, Alameda, USA; Vasco+35Aspi, Balt
Extrusion, Montmorency, France; Sophia 5/6F, Microvention,
Aliso Viejo, USA) was then advanced over the microcatheter
into the distal ICA. After crossing the intracranial thrombus over
themicrowire with themicrocatheter, mechanical thrombectomy
was performed with a Solitaire FR (ev3, Irvine, USA) or
Trevo (Stryker Neurovascular, Mountain View, USA). The
thrombectomy maneuver was also performed under flow arrest
with manual aspiration through the intermediate catheter
to prevent clot fragmentation and distal embolism. The
result of intracranial recanalization was evaluated using the
thrombolysis in cerebral infarction (TICI) score. Successful
recanalization was defined as TICI 2b or 3. If intracranial
recanalization was achieved, treatment of the cervical carotid
stenosis was left to the discretion of the operator, taking into
account residual cervical occlusion/severe stenosis or thrombus
apposition.
To perform cervical stenting or PTA, the 0.014“ microwire
was introduced into the petrous segment of the carotid artery
to preserve distal access. At one center, a distal filter protection
device (FilterWire EZ, Boston Scientific, Marlborough, USA)
was placed distal to the stenosis when anatomically possible.
Then, the guiding catheter and the intermediate catheter were
retrieved into the common carotid artery. A 250mg bolus
of aspirin was administered intravenously prior to stenting.
The decision to introduce double anti-platelet therapy with
75mg clopidogrel was taken following a control CT scan
within 24 h, depending on the presence of hemorrhagic
transformation or intracerebral hemorrhage. Cervical carotid
artery stenting was performed (Carotid Wallstent, Boston
Scientific, Natick, USA; Precise, Codman and Shurtleff,
Raynham, USA; Cristallo ideale, Invatec, Roncadelle, Italy;
Casper, Microvention, Tustin, USA; X-ACT, Abbott Vascular,
Redwood, USA). Appropriate positioning and opening of the
stent was immediately assessed angiographically and additional
angioplasty was performed if deemed necessary. In PTA-
only cases, PTA was performed using different PTA balloons
(Submarine Rapido, Invatec, Roncadelle, Italy; Aviator Plus,
Cordis, Freemont, USA; Ultrasoft balloon dilatation catheter,
Boston Scientific, Freemont,USA).
If initial passing through the stenosis with the guiding or
intermediate catheter was not possible, an antegrade (proximal-
to-distal) approach was used, i.e., first addressing the ICA
stenosis with PTA/stenting under proximal flow arrest using a
balloon-guiding catheter and/or a distal filter protection device
and then performing the intracranial thrombectomy as the
second step as described above.
In one center, in case of an efficient Circle of Willis and no
threatening cervical steno-occlusive lesion, the treatment of the
latter was deferred to the subacute phase (after 2–5 days) on a
semi-elective basis after initiating double anti-platelet therapy.
Follow-Up
Follow-up CT or MRI was performed 24 h after the acute therapy
to assess infarction volume and hemorrhagic status. Symptomatic
intracranial hemorrhage (sICH) was defined as a documented
hemorrhage associated with a decline of ≥4 points in the NIHSS
score. If no hemorrhage occurred, double anti-platelet therapy
was initiated and continued for 3–6 months. Single anti-platelet
treatment was then maintained for 1 year or lifelong depending
on the responsible center’s protocol.
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NIHSS was measured following recovery from the anesthetic,
and throughout hospitalization until discharge. Routine clinical
follow-up was performed at 3 months by an independent
neurologist to evaluate patients’ recovery, using themRS. Clinical
outcome was quantified by 3-months mRS and mortality.
Favorable outcome was defined as mRS ≤2.
Statistical Analysis
Group comparison of continuous or ordinally scaled variables
was carried out with the Mann-Whitney-U or Kruskal-Wallis
test depending on the number of groups. Frequency counts
were compared by applying Fisher’s exact test. For multivariable
logistic regression analysis, all variables with p < 0.150 in the
univariate analyses were included in the model. Analyses were
run using IBM SPSS Statistics v.21 (IBM, Armonk, NY, USA).
TABLE 1 | Clinical baseline, interventional and outcome characteristics.
Tandem intracranial-
extracranial
occlusions (N = 121)
Isolated intracranial
occlusions (N = 456)
P
BASELINE
Age (years) 72 (61–79) 70 (63–78) 0.544
Sex, female 25.6% (31/121) 50.4% (230/456) <0.001
Admission NIHSS 17 (IQR 12–20) 16 (IQR 13–21) 0.474
IVT 52.1% (63/121) 53.9% (246/456) 0.759
Intracranial occlusion
site
0.003
- M1 67.8% (82/121) 80.9% (369/456)
- ICA 32.2% (39/121) 19.1% (87/456)
Symptom-onset to
groin puncture (mins)
262 (IQR 194–356) 241 (IQR 190–315) 0.093
Atrial fibrillation 30.0% (36/120) 45.2% (192/425) 0.003
Diabetes 20.7% (25/121) 13.6% (62/455) 0.063
Arterial hypertension 62.8% (76/121) 65.2% (296/454) 0.669
Dyslipidemia 51.3% (61/119) 45.9% (208/453) 0.304
Smoking 45.8% (54/118) 24.2% (102/421) <0.001
INTERVENTIONAL
Procedure time 57 (IQR 87–115) 33 (IQR 49–89) <0.001
Number of maneuvers 1 (IQR 1–3) 1 (IQR 1–3) 0.495
Final TICI 2b/3 70.2% (85/121) 83.6% (381/456) 0.002
Complications 0.122
- None
- Dissection
- Perforation
- Other
- 89.3% (108/121)
- 7.4% (9/121)
- 2.5% (3/121)
- 0.8% (1/121)
- 93.2% (425/456)
- 5.7% (26/456)
- 0.4% (2/456)
- 0.7% (3/456)
Infarct in previously
unaffected territories
7.4% (9/121) 8.6% (39/456) 0.853
OUTCOME
sICH 10.7% (13/121) 6.9% (31/452) 0.177
aICH 29.8% (36/121) 17.09% (77/452) 0.003
90-day mRS 3 (IQR 1–4) 3 (IQR 1–4) 0.142
90-day mRS ≤ 2 42.4% (50/118) 49.6% (212/427) 0.177
90-day mortality 19.5% (23/118) 15.7% (67/427) 0.329
RESULTS
Clinical Baseline, Interventional and
Outcome Results in Tandem Occlusions
vs. Isolated Intracranial Occlusions
Between January 2010 and September 2015, 121 patients with
atherosclerotic tandem occlusions and 456 patients with isolated
carotid-T or M1 occlusions were consecutively treated in the two
participating institutions using mechanical thrombectomy with
stent-retrievers. Patients in the isolated intracranial occlusion
group were predominantly female (50.4 vs. 25.6%, p < 0.001).
Patients in the tandem occlusion group were more likely to
have a carotid-T occlusion (32.2 vs. 19.1%, p = 0.003) and to
be smokers (p < 0.001). Patients in the isolated intracranial
occlusion group had a higher prevalence of atrial fibrillation (p
= 0.003). There was no difference between the two groups in
NIHSS score at admission (17, interquartile range [IQR] 12–20
vs. 16, IQR 13–21, p = 0.474) and time from symptom-onset to
groin puncture (262min, IQR 194–356 vs. 241, IQR 190–315, p=
0.093). Procedure time was significantly shorter in the group with
isolated intracranial occlusion (33min, IQR 49–89 vs. 57min,
IQR 87–115, p< 0.001) and successful recanalization (TICI 2b/3)
was more frequent (83.6 vs. 70.2%, p = 0.002). There was no
difference in technical complication rate, including infarcts to
previously unaffected vessel territories. The rate of asymptomatic
TABLE 2 | Interventional and clinical outcome in patients with tandem occlusions
treated using the antegrade vs. retrograde approach.
Antegrade approach
(n = 46)
Retrograde
approach (n = 75)
P
INTERVENTIONAL
Age (years) 70 (63–79) 70 (63–76) 0.871
Sex, female 32.6% (15/46) 21.3% (16/31) 0.200
Admission NIHSS 18 (13–21) 16 (10–19) 0.077
Procedure time 95 (IQR 53–141) 82 (IQR 61–109) 0.251
Number of maneuvers 2 (IQR 1–3) 1 (IQR 1–2) 0.017
Intracranial final TICI
2b/3
65.2% (30/46) 73.3% (55/75) 0.414
Complications 0.305
- None
- Dissection
- Perforation
- Other
- 89.1% (41/46)
- 10.9% (5/56)
- 0% (0/46)
- 0% (0/46)
- 89.3% (67/75)
- 5.3% (4/75)
- 4.0% (3/75)
- 1.3% (1/75)
Infarct in previously
unaffected territories
13.0% (6/46) 4.0% (3/75) 0.082
sICH 10.9% (5/46) 10.7% (8/75) 1.000
aICH 28.3% (13/46) 30.7% (23/75) 0.840
Rethrombosis during
acute treatment
4.3% (2/46) 9.3% (7/75) 0.480
ICA patency at end of
procedure
100% (46/46) 97.3% (73/75) 0.525
ICA patency at day 7 93.5% (43/46) 85.1% (63/74) 0.244
90-day mRS 3 (IQR 1–4) 3 (IQR 1–5) 0.300
90-day mRS ≤2 46.7% (21/45) 39.7% (29/73) 0.565
90-day mortality 15.6% (7/45) 21.9% (16/73) 0.478
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ICH was higher in the tandem group (29.8 vs. 17.1%, p= 0.003);
however there was no significant difference in the rate of sICH
(10.7 vs. 6.9%, p = 0.177). Rate of good outcome (mRS ≤ 2) and
mortality at 90 days was similar in the tandem group and the
isolated intracranial occlusion group, (42.4 vs. 59.6%, p = 0.177;
and 19.5 vs. 15.7%, p = 0.329, respectively). Clinical baseline,
interventional and outcome characteristics are summarized in
Table 1.
Results of Management Strategies,
Technical and Clinical Outcome in the
Tandem Occlusion Group
Most of the patients in the tandem occlusion group were
treated using the retrograde approach 62% (75/121). There
was no difference in technical or clinical outcome related to
recanalization approach, except for a trend toward fewer distal
emboli when the retrograde approach was used (4.0 vs. 13.0%,
p = 0.082). Stenting of the extracranial ICA was performed
in 81% of patients (98/121), PTA alone in 7.4% (9/121), and
deferred stenting in 11.6% (14/121). There was a statistically non-
significant trend toward a higher rate of stent/ICA occlusion
within 7 days after PTA-only compared to stenting (33.3 vs.
10.3%, p= 0.127).
In the tandem occlusion group, age (p = 0.034), NIHSS
at admission (p = 0.002), recanalization rate (p < 0.001),
any complication (p = 0.016), and sICH (p = 0.001) were
associated with poor outcome, whereas extracranial treatment
modality (stenting, PTA-only, or deferred stenting) and stent
or ICA occlusion within 7 days did not affect outcome. In
multivariable logistic regression analysis, only NIHSS [aOR 0.89,
95% confidence intervals (CI) 0.82–0.97], age (aOR 0.95, 95% CI
0.91–0.99) and reperfusion success (aOR TICI2b/3 4.77, 95% CI
1.39–16.41) were associated with mRS ≤2. Data on the technical
and clinical outcome of patients in the tandem occlusion group
is summarized in Tables 2–4.
DISCUSSION
In patients with acute ischemic stroke, rapid recanalization
has been shown to have a strong influence on favorable
clinical outcome. Several recent randomized-controlled trials
have shown the superiority of endovascular mechanical
thrombectomy with stent-retrievers in large vessel occlusions
in acute ischemic stroke of the anterior circulation over
intravenous thrombolysis, achieving higher recanalization
rates and higher rates of good clinical outcome (9–11, 13, 18).
TABLE 3 | Interventional outcome in patients with tandem occlusions according to extracranial treatment modality.
PTA only (n = 9) Acute stenting
(n = 98)
Deferred stenting
(n = 14)
P
INTERVENTIONAL
Age, years 70 (IQR 65–86) 71 (IQR 63–78) 67 (IQR 55–76) 0.254
Sex, female 44.4% (4/9) 24.5% (24/98) 21.4% (3/14) 0.377
Admission NIHSS 11 (IQR 7–18) 17 (IQR 12–20) 18 (IQR 15–20) 0.094
Procedure time 71 (IQR 51–121) 92 (IQR 66–120) 75 (IQR 49–95) 0.269
Number of maneuvers 1 (IQR 1–2) 1 (IQR 1–3) 3 (IQR 2–3) 0.048
Intracranial final TICI
2b/3
77.8% (7/9) 69.4% (68/98) 71.4% (10/14) 0.932
Complications 0.398
- None
- Dissection
- Perforation
- Other
- 77.8% (7/9)
- 11.1% (1/9)
- 11.1% (1/9)
- 0% (0/9)
- 88.8% (87/98)
- 8.2% (8/98)
- 2.0% (2/98)
- 0% (0/98)
- 100% (14/14)
- 0% (0/14)
- 0% (0/14)
- 0% (0/14)
Infarct in previously
unaffected territories
0% (0/9) 8.2% (8/98) 7.1% (1/14) 1.000
sICH 0% (0/9) 12.2% (12/98) 7.1% (1/14) 0.739
aICH 22.2% (2/9) 31.6% (31/98) 21.4% (3/14) 0.694
Acute in-stent
thrombosis during
extracranial treatment
9.2% (9/98) 0% (0/14)
ICA patency at end of
procedure
100% (9/9) 98.0% (96/98) 100% (14/14) 1.000
ICA occlusion at day 7
after extracranial
procedure
33.3% (3/9) 10.3% (10/98) 7.1% (1/14) 0.127
90-day mRS 3 (1–4) 3 (1–5) 2 (0–3) 0.059
90-day mRS ≤2 37.5% (3/8) 39.6% (38/96) 64.3% (9/14) 0.231
90-day mortality 0% (0/8) 24.0% (23/96) 0% (0/14) 0.025
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TABLE 4 | Prognostic factors for good and poor outcome in patients with tandem
occlusions.
Good outcome
(90 days mRS ≤ 2,
n = 50)
Poor outcome
(90 days mRS > 2,
n = 68)
P
BASELINE
Age, years 67.2 ± 9.6 71.0 ± 9.5 0.034
Sex, female 26.0% (13/50) 25.0% (17/68) 1.000
Admission NIHSS 15 (10–18) 18 (14–21) 0.002
IVT 44.0% (22/50) 55.9% (38/68) 0.264
Intracranial occlusion site 0.079
- M1 76.0% (38/50) 60.3% (41/68)
- ICA 24.0% (12/50) 39.7% (27/68)
Symptom onset to groin
puncture (min)
259 (IQR 193–341) 279 (195–380) 0.365
Atrial fibrillation 26.5% (13/49) 30.9% (21/68) 0.682
Diabetes 14.0% (7/50) 25.0% (17/68) 0.170
Arterial hypertension 56.0% (28/50) 66.2% (45/68) 0.338
Dyslipidemia 54.2% (26/48) 50.0% (34/68) 0.708
Smoking 52.0% (26/50) 43.1% (28/65) 0.354
INTERVENTIONAL
Procedure time 74 (IQR 55–108) 94 (IQR 71–120) 0.122
Number of maneuvers 1 (IQR 1–2) 2 (IQR 1–3) 0.193
Final TICI 2b/3 88.0% (44/50) 55.9% (38/68) <0.001
Antegrade 42.0% (21/50) 35.3% (25/68) 0.565
Extracranial treatment
modality
0.231
- Acute stenting ± PTA 76.0% (38/50) 85.3% (58/68)
- PTA only 6.0% (3/50) 7.4% (5/68)
- Deferred stenting ±
PTA
18.0% (9/14) 7.4% (5/68)
ICA patency after 7 days 90.0% (45/50) 86.6% (58/67) 0.775
Any complications 8.0% (4/50) 26.5% (18/68) 0.016
sICH 0% (0/50) 19.1% (13/68) 0.001
aICH 28.0% (14/50) 30.9% (21/68) 0.839
However, approximately 20% of patients with an intracranial
large vessel occlusion of the anterior circulation have an
additional high-grade extracranial ICA stenosis or occlusion.
Stenotic or occlusive lesions of the ICA may be caused by
atherosclerotic disease, acute dissection or large thromboemboli.
These lesions are a major potential cause of intracranial
embolism in the carotid-T or the MCA as well as additional
concomitant hemodynamic impairment of brain perfusion. This
is associated with a risk of developing a large MCA infarction
with morbidity rates up to 70% and mortality rates up to
55% (19). Owing to the large clot burden and/or slow distal
flow, the combination of extracranial occlusive disease and
intracranial occlusion has shown a poor response to IVT with
recanalization rates only around 20% and poor outcome in up
to 80–100% (20). Therefore, endovascular treatment of tandem
occlusions with stent-retrievers with or without concomitant
extracranial PTA/stenting of the underlying obstructive lesion
is an emerging treatment option for this complex form of
ischemic stroke in order to achieve faster and higher rates of
recanalization. However, due to the greater severity of this
form of stroke and the technical complexity of endovascular
treatment of tandem occlusions, this subgroup of stroke patients
has been systematically excluded from most of the prospective
randomized-controlled trials. Several published studies have
shown that endovascular recanalization is technically feasible,
but complex. Successful recanalization rates have been achieved
in 60–80% of patients and a wide range of good clinical outcomes
from 39 to 63% has been reported (1–8, 14–16, 21). In our
study, rates of favorable clinical outcome and mortality were
similar in acute stroke patients with tandem lesions to those with
isolated intracranial large vessel occlusions. This emphasizes that
these patients have the chance of a similar clinical outcome and
endovascular treatment should be considered the standard of
care (22, 23).
Notably, the rate of successful recanalization (TICI ≥ 2B)
was lower in the tandem lesion group. It was, however, still
within the range reported in the literature for patients with
isolated large vessel occlusion of the anterior circulation treated
with mechanical thrombectomy using stent-retrievers (9–11, 13,
18). Overall, technical complications, including distal emboli in
previously unaffected territories and sICH, were similar despite
the more complex technical approaches needed for the tandem
occlusion group confirming a comparable overall safety profile.
Recanalization Strategies: Antegrade vs.
Retrograde Approach
Two different recanalization strategies have been proposed:
The “antegrade approach” (also called the proximal-to-distal
or extracranial-first approach) consists of first addressing the
extracranial carotid lesion using PTA and/or stenting and
recanalization of the intracranial occlusion using mechanical
thrombectomy second. This strategy may allow for safer access
to the intracranial lesion, better control of distal thromboemboli,
and may lower the risk of distal re-occlusion due to the re-
established and increased antegrade flow (3, 15, 24–28). However,
recanalization of the extracranial carotid lesion before treatment
of the distal intracranial lesion can be time-consuming and
can delay intracranial recanalization, potentially leading to a
less favorable outcome. Thus, the “retrograde approach” (also
known as the distal-to-proximal or intracranial-first approach)
aims at recanalization of the distal and symptomatic intracranial
occlusion first (3, 4, 17, 24, 25, 29–31). Rapid restoration of
perfusion to the affected territory first, by distal recanalization
using thrombectomy, shortens ischemic time and may increase
the likelihood of a favorable outcome. Once the distal occlusion
has been recanalized, time can be spent on definitively addressing
the carotid occlusive lesion. The major disadvantage of this
approach is that treating the carotid lesion after recanalization
of the distal occlusion may expose the patient to the potential
risk of distal embolization in the intracranial vasculature.
Therefore, additional protective measures such as the use of
distal filter protection devices or proximal balloon occlusion
during PTA/stenting have been advocated. In our study, the
preferred recanalization strategy was the retrograde approach.
However, the type of approach used did not affect procedure
Frontiers in Neurology | www.frontiersin.org 6 December 2018 | Volume 9 | Article 1046
Eker et al. Treatment of Atherosclerotic Tandem Occlusions
time, recanalization success or clinical outcome. Furthermore,
there was a statistically non-significant trend toward a higher
incidence of distal emboli using the antegrade approach. This
might be explained by the consequent flow arrest achieved during
intracranial thrombectomy using the retrograde approach and
proximal and/or simultaneous distal protection when addressing
the ICA stenotic lesion. These findings are in line with a
recent meta-analysis of the management of tandem occlusions
in patients with acute ischemic stroke (8). No differences were
observed in technical and clinical outcomes with respect to the
recanalization strategy except for a trend toward a higher rate
of procedure-related complications in patients treated with the
antegrade approach (20 vs. 8%, p= 0.25).
Extracranial Treatment Modalities and
Anti-platelet Therapy
Different extracranial treatment techniques have been advocated
to minimize the risk of re-occlusion, re-embolization, and
neurological deterioration related to hemodynamic impairment
due to symptomatic ICA stenosis. Stenting in the acute phase
enables the interventionalist to secure and protect a symptomatic
plaque and thus decrease the risk of recurrence of stroke
and re-establish flow in the case of hemodynamic impairment
allowing for a definitive, “one-stop” treatment of symptomatic
ICA stenosis. On the other hand, a PTA-only strategy also
enables treatment of hemodynamic impairment without the
need for anti-platelet therapy and deferred treatment by carotid
endarterectomy or stenting under “optimal” conditions (28, 29,
32, 33).
If carotid artery stent placement is necessary, anti-
thrombotic medication has to be administered to prevent
acute in-stent thrombosis carrying the risk of de-novo distal
thromboembolization or stent occlusion. However, giving any
kind of anti-thrombotic medication to patients with acute
stroke increases the risk of ICH (34, 35). Widely differing anti-
thrombotic treatment strategies are described in the literature.
The reported anti-thrombotic regimen includes administration
of aspirin alone or in combination with clopidogrel at various
dosages as well as the administration of glycoprotein IIb/IIIa
inhibitors and heparin. Rates of sICH of up to 30% have been
observed and anti-thrombotic treatment has been identified
as a major potential source of complications (34–36). In the
present study, anti-platelet monotherapy with 250mg of aspirin
was administered in the acute phase resulting in a similar rate
of sICH in the tandem lesion group to that in the group with
isolated occlusions, but with a higher rate of asymptomatic
ICH. These findings are in line with recently reported rates of
sICH in patients treated for tandem occlusions (5, 6, 8, 22, 36).
Furthermore, anti-platelet therapy with aspirin only after
bridging IVT did not lead to any increase in sICH or have a
negative effect on clinical outcome, a finding which is in line
with previously published data (34, 37, 38).
The risk of sICH after stenting in the acute phase has to be
balanced against the risk of stent occlusion or thrombosis and
its clinical consequences. As yet data on stent occlusion within
the first few days or its clinical relevance is scarce. In this series,
the rate of stent/ICA occlusion within 7 days after stenting in the
acute phase was 10.3% with a trend toward higher rates (33.3%)
after PTA-only. Interestingly, stent/ICA occlusion per se was not
associated with worse outcome and all affected patients remained
clinically asymptomatic. This might be due the long-standing
character of the atherosclerotic ICA stenosis leading eventually to
better hemodynamic tolerance of the occlusion without further
distal embolic events. Overall, technical complications did not
differ between the extracranial treatment modalities, which is in
agreement with previously reported data (8).
The results of our study suggest that anti-platelet therapy with
aspirin only in the acute phase of stroke does not significantly
increase the rate of sICH and has no overall negative impact
on clinical outcome irrespective of previously administered
bridging IVT. On the other hand, approximately 10% of stents
showed early occlusion, although in our series there were no
clinical consequences in terms of recurrence of stroke. Therefore,
stenting in the acute phase with aspirin only as an anti-platelet
therapy seems to yield an acceptable risk–benefit ratio in most
cases regarding rate of sICH and of stent occlusion.
Limitations
This study has inherent limitations due to the retrospective
design, although the data is derived from a prospectively
collected database. Moreover, the application of different
multimodal approaches for thrombectomy in the setting
of atherosclerotic tandem occlusion might confound the
treatment effect. Furthermore, the PTA-only and deferred-
stenting subgroups were significantly smaller than the stenting
group, limiting the comparability of the results. Finally, definitive
conclusions about the management of tandem occlusions cannot
be drawn from this study and further clinical studies, preferably
in the setting of a multicenter randomized-controlled trial, are
warranted, e. g. comparing safety, technique and outcome of
immediate vs. deferred stenting.
CONCLUSIONS
Endovascular treatment of tandem occlusions is technically
feasible, achieves recanalization rates and rates of good clinical
outcome comparable to those for isolated intracranial occlusions
and should therefore be considered to be the standard of care.
In cases of acute ICA stenting, the risk of stent occlusion and
sICH seems to be acceptable although it was associated with
an increased rate of asymptomatic ICH due to the need for
anti-platelet therapy.
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